Has everything really been discovered about SGLT2 inhibitors?

Česká verzia

Authors: Daša Skripová
Authors place of work: Diabetologická ambulancia ARETEUS s. r. o., Trebišov
Published in the journal: Diab Obez 2019; 19(38): 98-102
Category: Reviews

Výsledky veľkých randomizovaných klinických štúdií s novými skupinami antidiabetík (DPP4-inhibitórmi, GLP1 RA, gliflozínmi) zásadne ovplyvnili názory na liečbu a smerovanie súčasnej diabetológie. Okrem toho, čo si tieto klinické štúdie kládli primárne za úlohu, t.j. dokázať kardiovaskulárnu bezpečnosť nového antidiabetika, sa ukázalo, že niektoré majú kardioprotektívne účinky. Ovplyvnenie viacerých kardiometabolických rizikových faktorov aterosklerózy sa u diabetikov považuje za veľmi žiaduce, keďže veľká väčšina diabetikov 2 typu zomiera na kardiovaskulárne ochorenia.

Summary

The results of large randomized clinical trials with new classes of antidiabetic agents – ADAs (DPP4 inhibitors, GLP1RA, gliflozins), have fundamentally influenced the views on the management of type 2 diabetes mellitus. Besides the primary endpoint of these trials (to prove cardiovascular safety of each new ADA), some of ADAs in these trials have shown cardioprotective effects. Majority of type 2 diabetics die of cardiovascular disease (CVD), so influencing multiple cardiometabolic risk factors of atherosclerosis is highly desirable. In addition, some ADAs in cardiovascular outcome trials shown to have a renoprotective effect too, and to some extent delayed the onset and progression of chronic kidney disease (CKD).

Keywords:

cardioprotective effect – empagliflozin – EMPA-REG-OUTCOME Study – renoprotective effect – SGLT2

Zdroje

Frampton JE. Empagliflozin: A review in type 2 diabetes. Drugs 2018; 78(10): 1037–1048. Dostupné z DOI: <http://doi: 10.1007/s40265–018–0937-z>.
Inzucchi SE, Bergenstal RM, Buse JB et al. management of hyperglycemia in type 2 diabetes, 2015: a patient-centered aaprocach: update to a position statement if the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1):140–149. Dostupné z DOI: <http://doi: 10.2337/dc14–2441>.
Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SLGT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care 2016; 39(Suppl 2): S154-S164. Dostupné z DOI: <http://doi: 10.2337/dcS15–3005>.
Abdul-Ghani M, DelPrato S, Chilton R et al. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care 2016; 39(5): 717–725. Dostupné z DOI: <http://doi: 10.2337/dc16–0041>.
Scott LJ. Empagliflozin: a review of its use in patient in type 2 diabetes mellitus. Drugs 2014; 74 (15): 1769–1784. Dostupné z DOI: <http://doi: 10.1007/s40265–014–0298–1>.
Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014; 53(3): 213–225. Dostupné z DOI: <http://doi: 10.1007/s40262–013–0126-x>.
Roden M, Weng J, Eilbracht J et al. [EMPA-REG MONO trial investigators]. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1(3): 208–219. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(13)70084–6>.
Häring HU, Merker L, Seewaldt-Becker E et al. [EMPA-REG MET Trial Investigators]. Empagliflozin as add on to metformin in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37(6): 1650–1659. Dostupné z DOI: <http://doi: 10.2337/dc13–2105>.
Haring HU, Merkel L, Seewaldt-Becker E et al. [EMPA-REG METSU Trial Investigators]. Empagliflozin as add on to metformin plus sulphonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36(11): 3396–3404. Dostupné z DOI: <http://doi: 10.2337/dc12–2673>.
Kovacs CS, Seshiah V, Swallow R et al. [EMPA-REG PIO™ trial investigators]. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16 (2):147–158. Dostupné z DOI: <http://doi: 10.1111/dom.12188>.
Softeland E, Meier JJ, Vangen B et al. Empagliflozin as add on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, paralled-group trial. Diabetes Care 2017; 40(2): 201–209. Dostupné z DOI: <http://doi: 10.2337/dc16–1347>.
Ridderstale M, Andersen RK, Zeller C et al. [EMPA-REG H2H-SU trial investigators]. Comparison of empagliflozin and glimepiride as add on to metformin in patients with type 2 diabetes: a 104-week, randomized, active-contolled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2(3): 691–700. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(14)70120–2>.
Rosenstock J, Jelaska A, Zeller C et al. [EMPA-REG BASALTM trial investigators]. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately conctrolled on basal nsulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17(10): 936–948. Dostupné z DOI: <http://doi: 10.1111/dom.12503>.
Barnett AH, Mithhal A, Manassie J et al. [EMPA-REG RENAL trial investigators]. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomized, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2(5): 369–384. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(13)70208–0>.
Tikkanen I, Narko K, Zeller C et al. [EMPA-REG BP Investigators]. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38(3) :420–428. Dostupné z DOI: <http://doi: 10.2337/dc14–1096>.
Rosenstock J, Jelaska A, Frappin G et al. [EMPA-REG MDI Trial Investigators]. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37(7): 1815–1823. Dostupné z DOI: <http://doi: 10.2337/dc13–3055>.
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13:102. Dostupné z DOI: <http://doi: 10.1186/1475–2840–13–102>.
Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1504720>.
Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1611925>.
Tkáč I. Výsledky štúdie CREDENCE (Canagliflozin in Renal Events in Diabetes with Establisched Nephopathy) a jej možné implikácie pre klinickú prax. Interná Med 2019; 19(4): 125–127.
Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31–39. Dostupné z DOI: <http://doi: 10.1016/S0140–6736(18)32590-X>.
Wiviott SD, Raz I, Bonaca MP et al. [DECLARE–TIMI 58 Investigators]. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1812389>.
Paterno E, Pawar A, Franklin J et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation 2019; 139(25): 2822–2830. Dostupné z DOI: <http://doi: 10.1161/CIRCULATIONAHA.118.039177>.
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018; 61(10): 2108–2117. Dostupné z DOI: <http://doi: 10.1007/s00125–018–4670–7>.
Kohler S, Zeller C, Illiev H et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 2017; 34(7): 1707–1726. Dostupné z DOI: <http://doi: 10.1007/s12325–017–0573–0>.
Jardiance. Súhrn charakteristických vlastností lieku. Informácie dostupné z WWW: <https://www.sukl.sk/hlavna-stranka/slovenska-verzia/pomocne-stranky/detail-lieku?page_id=386&lie_id=0698B>.
Davies MJ, D´Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://doi: 10.2337/dci18–0033>.